Year: 2022

Biocytogen27s_LOGO

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

BEIJING, China & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--#Biocytogen--Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing)...